Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN5381 in Healthy and Hypertensive Adults
NCT04506645Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing REGN5381 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2020; status: completed.
02
Drugs
REGN5381
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04506645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506645.